HRP20251264T1 - Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom - Google Patents

Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom

Info

Publication number
HRP20251264T1
HRP20251264T1 HRP20251264TT HRP20251264T HRP20251264T1 HR P20251264 T1 HRP20251264 T1 HR P20251264T1 HR P20251264T T HRP20251264T T HR P20251264TT HR P20251264 T HRP20251264 T HR P20251264T HR P20251264 T1 HRP20251264 T1 HR P20251264T1
Authority
HR
Croatia
Prior art keywords
gemcitabine
bladder
per day
medicament
patient
Prior art date
Application number
HRP20251264TT
Other languages
English (en)
Croatian (hr)
Inventor
Dennis GIESING
Heejin Lee
Karen Daniel
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of HRP20251264T1 publication Critical patent/HRP20251264T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
HRP20251264TT 2014-03-06 2015-03-06 Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom HRP20251264T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461949215P 2014-03-06 2014-03-06
EP22196596.5A EP4124339B1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Publications (1)

Publication Number Publication Date
HRP20251264T1 true HRP20251264T1 (hr) 2025-12-05

Family

ID=52697553

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20251264TT HRP20251264T1 (hr) 2014-03-06 2015-03-06 Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
HRP20221252TT HRP20221252T1 (hr) 2014-03-06 2015-03-06 Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20221252TT HRP20221252T1 (hr) 2014-03-06 2015-03-06 Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom

Country Status (24)

Country Link
US (3) US20150250717A1 (enExample)
EP (2) EP3113782B1 (enExample)
JP (4) JP6901858B2 (enExample)
KR (1) KR102338079B1 (enExample)
CN (2) CN106102751A (enExample)
AU (4) AU2015226901B2 (enExample)
BR (1) BR112016020381A8 (enExample)
CA (1) CA2939979C (enExample)
DK (2) DK4124339T3 (enExample)
ES (1) ES2930435T3 (enExample)
FI (1) FI4124339T3 (enExample)
HR (2) HRP20251264T1 (enExample)
HU (1) HUE060704T2 (enExample)
IL (2) IL247347B2 (enExample)
LT (2) LT3113782T (enExample)
MX (1) MX2016011333A (enExample)
PL (2) PL3113782T3 (enExample)
PT (2) PT3113782T (enExample)
RS (2) RS67337B1 (enExample)
RU (1) RU2694902C1 (enExample)
SG (2) SG11201607342QA (enExample)
SI (1) SI4124339T1 (enExample)
SM (2) SMT202200449T1 (enExample)
WO (1) WO2015134911A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102383496B1 (ko) 2012-08-31 2022-04-08 타리스 바이오메디컬 엘엘씨 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
WO2015026813A1 (en) 2013-08-19 2015-02-26 Taris Biomedical Llc Multi-unit drug delivery devices and methods
HRP20251264T1 (hr) * 2014-03-06 2025-12-05 Taris Biomedical Llc Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
ES2940227T3 (es) 2016-05-06 2023-05-04 Taris Biomedical Llc Método de tratamiento del cáncer urotelial del tracto inferior
WO2019023388A1 (en) * 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
PE20210041A1 (es) * 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
CA3107461A1 (en) 2018-08-01 2020-02-06 Taris Biomedical Llc Methods of treating overactive bladder using trospium
JP7660066B2 (ja) * 2019-10-03 2025-04-10 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム
RU2713443C2 (ru) * 2019-11-01 2020-02-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0
US20230073301A1 (en) * 2020-01-27 2023-03-09 Isola Therapeutics, Inc. Tissue dosing for intraluminal local drug delivery
CN112169066B (zh) * 2020-10-29 2023-05-12 安徽省立医院(中国科学技术大学附属第一医院) 具有控制器的连续缓释给药留置管
CN113616666A (zh) * 2021-08-24 2021-11-09 傅广波 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
WO2004026281A2 (en) * 2002-09-23 2004-04-01 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
EP1613389B8 (en) * 2003-03-31 2008-05-07 Intarcia Therapeutics, Inc. Osmotic pump with means for dissipating internal pressure
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
US20100003297A1 (en) 2005-08-11 2010-01-07 Massachusetts Institute Of Technology Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
DK2231254T3 (da) 2007-12-11 2014-07-21 Massachusetts Inst Technology Implanterbar lægemiddelafgivelsesindretning
US8343516B2 (en) 2009-06-26 2013-01-01 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US8679094B2 (en) 2009-12-17 2014-03-25 Taris Biomedical, Inc. Implantable device with intravesical tolerability and methods of treatment
ES2732150T3 (es) * 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
US8690840B2 (en) 2010-10-06 2014-04-08 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
WO2012106714A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
KR102383496B1 (ko) * 2012-08-31 2022-04-08 타리스 바이오메디컬 엘엘씨 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
EP2968120A1 (en) 2013-03-15 2016-01-20 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
WO2015026813A1 (en) * 2013-08-19 2015-02-26 Taris Biomedical Llc Multi-unit drug delivery devices and methods
KR20160083061A (ko) * 2013-11-05 2016-07-11 타리스 바이오메디컬 엘엘씨 삼투 약물 전달 디바이스들, 키트, 및 방법들
HRP20251264T1 (hr) * 2014-03-06 2025-12-05 Taris Biomedical Llc Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom

Also Published As

Publication number Publication date
EP4124339B1 (en) 2025-09-10
WO2015134911A1 (en) 2015-09-11
CN106102751A (zh) 2016-11-09
RS67337B1 (sr) 2025-11-28
US20150250717A1 (en) 2015-09-10
LT4124339T (lt) 2025-11-10
AU2022215156A1 (en) 2022-09-01
AU2015226901A1 (en) 2016-09-01
JP2019218410A (ja) 2019-12-26
ES2930435T3 (es) 2022-12-13
JP2017508749A (ja) 2017-03-30
US20220347091A1 (en) 2022-11-03
JP2024009034A (ja) 2024-01-19
CA2939979C (en) 2023-03-21
PL4124339T3 (pl) 2025-11-17
KR20160124425A (ko) 2016-10-27
PL3113782T3 (pl) 2023-01-23
IL311410B1 (en) 2025-07-01
DK3113782T3 (da) 2022-10-17
HUE060704T2 (hu) 2023-04-28
PT4124339T (pt) 2025-11-04
SMT202200449T1 (it) 2023-01-13
PT3113782T (pt) 2023-01-05
KR102338079B1 (ko) 2021-12-09
CA2939979A1 (en) 2015-09-11
JP6901858B2 (ja) 2021-07-14
EP4124339A1 (en) 2023-02-01
EP3113782B1 (en) 2022-09-28
US20220117886A1 (en) 2022-04-21
BR112016020381A8 (pt) 2018-05-02
AU2020217383B2 (en) 2022-09-08
CN119950539A (zh) 2025-05-09
RS63675B1 (sr) 2022-11-30
AU2024259822A1 (en) 2024-11-28
AU2020217383A1 (en) 2020-09-03
IL311410A (en) 2024-05-01
BR112016020381A2 (pt) 2017-08-15
MX2016011333A (es) 2016-12-07
SMT202500385T1 (it) 2025-11-10
JP7383681B2 (ja) 2023-11-20
SI4124339T1 (sl) 2025-11-28
JP2022022235A (ja) 2022-02-03
IL311410B2 (en) 2025-11-01
NZ723303A (en) 2023-10-27
IL247347B2 (en) 2025-03-01
EP3113782A1 (en) 2017-01-11
HRP20221252T1 (hr) 2022-12-09
AU2015226901B2 (en) 2020-05-14
SG10202101978SA (en) 2021-04-29
DK4124339T3 (da) 2025-10-13
IL247347B1 (en) 2024-11-01
FI4124339T3 (fi) 2025-10-17
RU2694902C1 (ru) 2019-07-18
LT3113782T (lt) 2022-11-25
SG11201607342QA (en) 2016-10-28
AU2022215156B2 (en) 2024-09-05
IL247347A0 (en) 2016-11-30
JP7061595B2 (ja) 2022-04-28

Similar Documents

Publication Publication Date Title
HRP20251264T1 (hr) Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
HRP20211921T1 (hr) Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s oksaliplatinom
JP2017508749A5 (enExample)
MX2020002465A (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior.
CA3045436C (en) Posterior segment drug delivery
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
HRP20191285T1 (hr) Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
RU2016147523A (ru) Лечение гиперкинетических двигательных расстройств
WO2012071559A3 (en) Therapeutic methods and compositions for solid delivery
RU2015109298A (ru) Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
JP2013541583A5 (enExample)
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
HRP20191248T1 (hr) Kombinirana terapija za liječenje karcinoma jajnika
JP2018138596A5 (enExample)
MX2018004695A (es) Composiciones de proteinas estables.
HRP20181079T1 (hr) Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
AR111803A1 (es) Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino
ES2572180T3 (es) Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции